Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial

Eliel Bayever, Patrick L. Iversen, Michael R. Bishop, J. Graham Sharp, Hemant K. Tewary, Mark A. Arneson, Samuel J. Pirruccello, Raymond W. Ruddon, A. Kessinger, Gerald Zon, James O. Armitage

Research output: Contribution to journalArticle

140 Scopus citations

Abstract

A synthetic phosphorothioate oligonucleotide was administered systemically to five patients with either relapsed or refractory acute myelogenous leukemia (AML), or myelodysplastic syndrome (MDS). Patients received a 10-day continuous intravenous infusion of this compound, which is complementary to p53 mRNA. No major toxicity attributable to a dose of 0.05 mg/kg/hr was observed. A range of approximately 9 to 18% of the administered dose was recovered in the urine as intact oligonucleotide. Evaluation of malignant cells recovered from bone marrow and peripheral blood at intervals before, during, and after treatment reveals no enhanced growth potential following oligonucleotide administration. Hence, a phosphorothioate oligonucleotide complementary to p53 mRNA can be administered at this dose level to humans without major toxicity. Higher doses need to be evaluated for toxicity and potential clinical efficacy.

Original languageEnglish (US)
Pages (from-to)383-390
Number of pages8
JournalAntisense Research and Development
Volume3
Issue number4
DOIs
StatePublished - 1993

ASJC Scopus subject areas

  • Genetics

Fingerprint Dive into the research topics of 'Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial'. Together they form a unique fingerprint.

  • Cite this